India’s Welfo To Market Second-Line Anti-Malarial Drug Early In 2008 (India)
This article was originally published in PharmAsia News
Executive Summary
Welfo Pharmaceuticals of India plans to market a second-line malaria drug Maligo (dihydroartemisinin derivate) early next year. The company also says the drug is useful for patients who have become resistant to chloroquinine, the common malaria treatment. Other drugs with the same active ingredient are in use in India, but Maligo is considered most effective when combined with Holleykin Pharmaceuticals' anti-malarial drug, Artekin (piperaquine), already available in China. (Click here for more